Distinguished in Leukemia

Dr. Ron Ram

Hematology
825 Eastlake Ave E, 
Seattle, WA 
Distinguished in Leukemia
825 Eastlake Ave E, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ron Ram is a Hematologist in Seattle, Washington. Dr. Ram is rated as a Distinguished provider by MediFind in the treatment of Leukemia. His top areas of expertise are Febrile Neutropenia, Agranulocytosis, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Graft.

His clinical research consists of co-authoring 121 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 37 articles and participated in 3 clinical trials in the study of Leukemia.

Specialties
Hematology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
Enrollment Status: Terminated
Publish Date: May 24, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: ATIR101 Ex Vivo-Depleted T Lymphocyte-Enriched Leukocyte, Cyclophosphamide
Study Phase: Phase 3
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

121 Total Publications

Bronchiectasis as a distinct entity in patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
Bronchiectasis as a distinct entity in patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
Journal: Transplantation and cellular therapy
Published: September 06, 2025
Similar Doctors
Elite in Leukemia
Dr. Roland B. Walter
Hematology
Elite in Leukemia
Dr. Roland B. Walter
Hematology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (1.9 miles away)
206-598-4333
Languages Spoken:
English, Arabic, Filipino, French, German, Hindi, Mandarin, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Roland Walter is a Hematologist in Seattle, Washington. Dr. Walter is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Febrile Neutropenia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Walter is currently accepting new patients.

Elite in Leukemia
Dr. Mazyar S. Shadman
Hematology Oncology | Oncology | Hematology
Elite in Leukemia
Dr. Mazyar S. Shadman
Hematology Oncology | Oncology | Hematology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Farsi, Hebrew, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mazyar Shadman is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Shadman is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Shadman is currently accepting new patients.

Ryan D. Cassaday
Elite in Leukemia
Dr. Ryan D. Cassaday
Hematology Oncology | Hematology | Oncology
Elite in Leukemia
Dr. Ryan D. Cassaday
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Mandarin, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Ryan Cassaday is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Cassaday is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Cassaday is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ram's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile